drugset / Trial / NCT07557615
hCG Treatment for Rehabilitation From a TBI
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2029-07-01
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ovidrel | Protein / enzyme biologic | 125 ug | Subcutaneous |